Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc., and Seagen Inc.

Medical Crossfire®: How Should We Leverage Immunotherapeutic and Targeted Strategies Across Lines of Care in Bladder Cancer?

Release Date: November 3, 2021
Expiration Date: November 3, 2022

Activity Overview

This on-demand virtual symposium brings together renowned experts who are well-versed in the treatment of bladder cancer. The program will begin with an overview of biomarker testing and its utility in the treatment decision-making process, followed by detailed case presentations, and panel discussions on controversial issues. The overarching goal of this program is to provide up-to-date information regarding the efficacy and safety of immunotherapies and targeted agents for bladder cancer across the disease spectrum and help physicians better understand clinical scenarios in which individualizing treatment would optimize patient outcomes.
 
This educational activity is an archive of a live virtual symposium held on October 20, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc., and Seagen Inc.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward oncologists, urologists, and researchers interested in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with bladder cancers will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline biomarker testing and interpretation to guide treatment options for immunotherapies and targeted agents in bladder cancer.
  • Evaluate efficacy and safety data from clinical trials of emerging single agent and combination therapeutic approaches across lines of care in bladder cancer.
  • Integrate biomarker testing and recent evidence on systemic treatment strategies to optimize care for early and advanced bladder along the care continuum.
  • Apply monitoring and mitigation strategies for adverse events associated with targeted and immunotherapeutic treatment options in bladder cancer.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 

Chair

Arjun V. Balar, MD
Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Medical Director, Clinical Trials Office
Perlmutter Cancer Center at NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: Genentech, Inc.; Merck & Co., Inc.; AstraZeneca/Medimmune, Nektar Therapeutics; Seagen Inc.; Immunomedics/Gilead Sciences; Consultant: Genentech, Inc.; Incyte Corp.; Janssen Pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.; AstraZeneca/Medimmune, Nektar Therapeutics; Seagen Inc.; Immunomedics/Gilead Sciences; Istari Oncology; Speakers’ Bureau: Genentech, Inc.; Merck & Co., Inc.; AstraZeneca/Medimmune; Other: Steering/Scientific Advisory Committee: Merck & Co., Inc.; Nektar Therapeutics; Equity, Scientific Advisory Board Member: EpiVax Oncology, GT Biopharma, Inc.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director/, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director
Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of MedicCharlottesville, VA

Disclosures: Grant/Research Support: Scripps Research, Bristol Myers Squibb, Arvinas; Consultant: Astellas Pharma Inc.; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer; Bristol Myers Squibb; Eisai Co., Ltd.; Exelixis, Inc.; EMD Serono Inc.; Gilead Sciences; Hinova Pharmaceuticals Inc.; Infinity Pharmaceuticals; Janssen Pharmaceuticals; Merck & Co., Inc.; Myovant Sciences; Pfizer Inc.; Propella Therapeutics Inc.; Seattle Genetics

Sima Porten, MD, MPH, FACS
Sima Porten, MD, MPH, FACS
Associate Professor
Department of Urology
University of California San Francisco
San Francisco, CA

Disclosures: Grant/Research Support: Photocure ASA; Consultant: Photocure ASA, Protara Therapeutics.

Scott T. Tagawa, MD, MS, FACP
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine (Division of Hematology, & Medical Oncology, Department of Medicine Professor of Medicine in Urology)
Department of Urology
Medical Director, Genitourinary Oncology Research Program
Leader, GU Disease Management Team
Meyer Cancer Center
NewYork-Presbyterian Hospital – Weill Cornell Medical Center
New York, NY

Disclosures: Grant/Research Support: Sanofi Genzyme; Medivation; Astellas Pharma Inc.; Janssen Pharmaceuticals; Amgen Inc.; Progenics Pharmaceuticals, Inc.; Dendreon Pharmaceuticals; Eli Lilly and Company, Genentech, Inc.; Newlink Genetics; Bristol Myers Squibb; Inovio Pharmaceuticals, Inc.; AstraZeneca; Immunomedics; AVEO Pharmaceuticals, Inc.; Rexahn Pharmaceuticals, Inc., Atlab Pharma; Boehringer Ingelheim, Millennium Pharmaceuticals, Inc.; Bayer Pharmaceuticals; Merck & Co., Inc.; AbbVie Inc.; Karyopharm Therapeutics; Endocyte, Inc.; Clovis Oncology; Seattle Genetics; Novartis; Gilead Sciences; POINT Biopharma; Consultant: Sanofi Genzyme; Medivation/Astellas Pharma Inc.; Dendreon Pharmaceuticals; Janssen Pharmaceuticals; Genentech, Inc.; Bayer Pharmaceuticals; Endocyte, Inc.; Eisai Co., Ltd.; Immunomedics; Karyopharm Therapeutics; AbbVie Inc.; Tolmar Inc.; Seattle Genetics; Amgen Inc.; Clovis Oncology; QED Therapeutics; Pfizer Inc.; AAA, a Novartis Company; Clarity Pharmaceuticals; Genomic Health; POINT Biopharma; Blue Earth Diagnostics; AIkido Pharma Inc.; Telix Pharmaceuticals; Convergent Therapeutics; Stock/Shareholder: AIkido Pharma Inc.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By